Silence Therapeutics (SLN)
Silence Therapeutics Statistics
Share Statistics
Silence Therapeutics has 47.22M shares outstanding. The number of shares has increased by 204.18% in one year.
| Shares Outstanding | 47.22M |
| Shares Change (YoY) | 204.18% |
| Shares Change (QoQ) | 200.06% |
| Owned by Institutions (%) | 17.68% |
| Shares Floating | 37.56M |
| Failed to Deliver (FTD) Shares | 4.67K |
| FTD / Avg. Volume | 1.65% |
Short Selling Information
The latest short interest is 353.32K, so 0.75% of the outstanding shares have been sold short.
| Short Interest | 353.32K |
| Short % of Shares Out | 0.75% |
| Short % of Float | 0.94% |
| Short Ratio (days to cover) | 2.36 |
Valuation Ratios
The PE ratio is -7.17 and the forward PE ratio is -10.71. Silence Therapeutics's PEG ratio is 0.44.
| PE Ratio | -7.17 |
| Forward PE | -10.71 |
| PS Ratio | 7.51 |
| Forward PS | 0.5 |
| PB Ratio | -2.42 |
| P/FCF Ratio | -4.79 |
| PEG Ratio | 0.44 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Silence Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.14, with a Debt / Equity ratio of 0.
| Current Ratio | 11.14 |
| Quick Ratio | 11.14 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $372.91K |
| Profits Per Employee | $-390.59K |
| Employee Count | 116 |
| Asset Turnover | 0.21 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 845K |
| Effective Tax Rate | -1.9% |
Stock Price Statistics
The stock price has increased by -87.61% in the last 52 weeks. The beta is 1.25, so Silence Therapeutics's price volatility has been higher than the market average.
| Beta | 1.25 |
| 52-Week Price Change | -87.61% |
| 50-Day Moving Average | 4.38 |
| 200-Day Moving Average | 12.37 |
| Relative Strength Index (RSI) | 31.64 |
| Average Volume (20 Days) | 282.69K |
Income Statement
In the last 12 months, Silence Therapeutics had revenue of 43.26M and earned -45.31M in profits. Earnings per share was -0.33.
| Revenue | 43.26M |
| Gross Profit | 31.45M |
| Operating Income | -63.32M |
| Net Income | -45.31M |
| EBITDA | -48.99M |
| EBIT | -49.58M |
| Earnings Per Share (EPS) | -0.33 |
Balance Sheet
The company has 121.33M in cash and 117K in debt, giving a net cash position of 121.21M.
| Cash & Cash Equivalents | 121.33M |
| Total Debt | 117K |
| Net Cash | 121.21M |
| Retained Earnings | 474.04M |
| Total Assets | 202.63M |
| Working Capital | 170.54M |
Cash Flow
In the last 12 months, operating cash flow was -67.64M and capital expenditures -211K, giving a free cash flow of -67.85M.
| Operating Cash Flow | -67.64M |
| Capital Expenditures | -211K |
| Free Cash Flow | -67.85M |
| FCF Per Share | -0.48 |
Margins
Gross margin is 72.7%, with operating and profit margins of -146.38% and -104.74%.
| Gross Margin | 72.7% |
| Operating Margin | -146.38% |
| Pretax Margin | -102.79% |
| Profit Margin | -104.74% |
| EBITDA Margin | -113.25% |
| EBIT Margin | -146.38% |
| FCF Margin | -156.85% |
Dividends & Yields
SLN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for SLN is $45, which is 1617.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $45 |
| Price Target Difference | 1617.6% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | -1.53 |
| Piotroski F-Score | 2 |